Texas Biomed tapped for national ‘Dream Team’ developing antivirals against COVID-19 and other threats

Texas Biomedical Research Institute Professor Luis Martinez-Sobrido, PhD, an expert in virology, vaccines and antiviral research, has been recruited to collaborate with three of the nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern announced by NIH this spring.

Unexpected link between most common cancer drivers may yield more effective drugs

Two of the most common genetic changes that cause cells to become cancerous, which were previously thought to be separate and regulated by different cellular signals, are working in concert, according to new research from the University of Wisconsin–Madison. To date, researchers have focused on finding drugs that block one or the other to treat cancer.

MD Anderson Research Highlights for June 1, 2022

Current advances include new biomarkers to predict chimeric antigen receptor (CAR) T cell therapy outcomes and neurotoxicities, novel treatment targets for pre-cancerous pancreatic lesions and T-cell acute lymphoblastic leukemia, a new approach to improve immunotherapy responses in cold tumors, a profile of synthetic lethal targets for cancers with tumor suppressor loss, and promising clinical data for acute myeloid leukemia and cancers of unknown primary.

Mount Sinai Microbiome Lab Joins NIH’s Accelerating Medicines Partnership

The National Institutes of the Health (NIH) has awarded researchers at the Icahn School of Medicine at Mount Sinai a four-year grant to study the role of the human microbiome in rheumatoid arthritis, systemic lupus, and other autoimmune diseases. The grant is part of the NIH’s Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Diseases (AMP® AIM) program, which is designed to speed the discovery of new treatments and diagnostics. It will support the Microbiome Technology and Analytic Center Hub (Micro-TEACH), a multidisciplinary team of researchers at Icahn Mount Sinai and NYU Langone Health.

COVID-19, MIS-C and Kawasaki Disease Share Same Immune Response

COVID-19, MIS-C and KD all share a similar underlying mechanism involving the over-activation of particular inflammatory pathways, UC San Diego study shows. Findings support novel drug targets for MIS-C.

UAH collaboration creates self-learning AI platform to discover new drugs

A cross-college collaboration at The University of Alabama in Huntsville (UAH) has developed a self-learning artificial intelligence (AI) platform that uses big data analytics to discover how new pharmaceutical drugs and various molecules work inside living cells.

Harrington Discovery Institute Announces 2022 Grant Funding to 11 Physician-Scientists

Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, today announced the 2022 class of Harrington Scholar-Innovators. The scholar awards will support a diverse set of drug discovery projects including new treatments for pulmonary diseases, COVID-19, multiple cancers, corneal disease, hepatitis, and acquired spinal cord injuries.

This class of microbes is an underexploited source of new bioactive compounds

Demand for new kinds of antibiotics is surging, as drug-resistant and emerging infections are becoming an increasingly serious global health threat. Researchers are racing to reexamine certain microbes that serve as one of our most successful sources of therapeutics: the…

ELRIG Drug Discovery 2021 Hosts Six SLAS Innovation AveNEW Companies

The Society for Laboratory Automation and Screening (SLAS) will host its popular Innovation AveNEW for startups at Drug Discovery 2021 in Liverpool, UK on October 19-20. Presented by The European Laboratory Research & Innovation Group (ELRIG), Drug Discovery 2021 returns to an in-person meeting format with a mission to engage quality discussions on key issues and future directions in preclinical drug discovery.

SLAS Discovery’s September Special Collection “Applications of Biophysics in Early Drug Discovery” Now Available

The September edition of SLAS Discovery is a Special Collection featuring the cover article, “Applications of Biophysics in Early Drug Discovery” by Geoffrey A. Holdgate (AstraZeneca, Macclesfield, UK) and Christian Bergsdorf, Ph.D. (Novartis Institutes for Biomedical Research, Basel, Switzerland).

When stubborn bugs refuse to make drugs

An untapped trove of desirable drug-like molecules is hidden in the genomes of Streptomyces bacteria — the same bacteria responsible for the first bacterial antibiotics to treat tuberculosis back in the 1940s. Isolating them, however, has proved challenging. Now, biologists at Washington University in St. Louis are using comparative metabologenomics to try to uncover what may be “silencing” Streptomyces and preventing it from producing desirable compounds encoded by its genes.

SLAS Discovery’s August Special Collection “Approaches for Prioritizing High-Quality Chemical Matter in Chemical Probe and Drug Discovery” Now Available

The August edition of SLAS Discovery is a Special Collection featuring the cover article, “Approaches for Prioritizing High-Quality Chemical Matter in Chemical Probe and Drug Discovery” by Jayme L. Dahlin, M.D., Ph.D. (Brigham and Women’s Hospital, Boston, MA, USA).

Population-specific diversity within fungi species could enable improved drug discovery

Scientists at Oak Ridge National Laboratory and the University of Wisconsin–Madison have discovered that genetically distinct populations within the same species of fungi can produce unique mixes of secondary metabolites, which are organic compounds with applications in medicine, industry and agriculture.

SLAS Discovery’s July Special Edition “Drug Discovery Targeting COVID-19” Now Available

The July edition of SLAS Discovery is a Special Edition featuring the cover article, “Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry” by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).

SLAS Discovery’s “A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities” Available Now

The June edition of SLAS Discovery features the cover article, “A Perspective on Synthetic Biology in Drug Discovery and Development—Current Impact and Future Opportunities” by Florian David, Ph.D. (Chalmers University of Technology, Gothenburg, Sweden), Andrew M. Davis, Ph.D. (AstraZeneca, Cambridge, England, UK). Michael Gossing, Ph.D., Martin A. Hayes, Ph.D., and Elvira Romero, Ph.D., and Louis H. Scott, Ph.D. (AstraZeneca, Gothenburg, Sweden), and Mark J. Wigglesworth, Ph.D. (AstraZeneca, London, England, UK).

More than 1,000 SARS-CoV-2 Coronavirus Protein 3D Structures Available

New Brunswick, N.J. (March 3, 2021) – The 3D structures of more than 1,000 SARS-CoV-2 coronavirus proteins are freely available from the RCSB Protein Data Bank headquartered at Rutgers University–New Brunswick. The data bank reached the milestone this week, with 1,018 proteins as…

Harnessing the Power of Proteins in our Cells to Combat Disease

A lab on UNLV’s campus has been a hub of activity in recent years, playing a significant role in a new realm of drug discovery — one that could potentially provide a solution for patients who have run out of options.

Students Identify Starting Points for Potential COVID-19 Inhibitors

Two students working under the mentorship of Desigan Kumaran, a structural biologist at the U.S. Department of Energy’s Brookhaven National Laboratory, have helped to identify molecules that could potentially lead to new antiviral drugs for treating COVID-19. Though the students conducted their fall 2020 internships remotely, the potential of their work is firmly planted in the real world and could have lasting impact.

PhRMA Foundation Awards More than $1 Million to Support Young Scientists with Grants and Fellowships in Drug Discovery and Drug Delivery

The PhRMA Foundation announced the first recipients of its new funding awards in Drug Discovery and Drug Delivery, designed to support the innovative biopharmaceutical research projects of talented young scientists in the United States. A total of 16 recipients were selected and more than $1 million was awarded.

NYU, Columbia, and Takeda Form Research Alliance for Gastrointestinal and Liver Disorders

New York University, Columbia University, and Takeda Pharmaceutical Company Limited (“Takeda”) have formed a collaborative research alliance to begin and advance gastroenterology research programs, with the goal of developing new therapies for patients with gastrointestinal and liver disorders.

University of Utah to speed process of bringing new therapeutics to patients

The Huntsman Cancer Institute, College of Pharmacy and PIVOT Center have partnered to establish the University of Utah Therapeutic Accelerator Hub. The new Accelerator will provide resources and expertise to researchers to support the process of translating research discoveries into innovative clinical applications.

Dopamine Surge Reveals How Even for Mice, ‘There’s No Place Like Home’

“There’s no place like home,” has its roots deep in the brain. Using fiber photometry, scientists are the first to show that home evokes a surge of dopamine in mice that mimics the response to a dose of cocaine. The study demonstrates how dopamine rises rapidly in mice moved from a simple recording chamber to their home cage, but less so when they return to a cage not quite like the one they knew.

Steady Progress in the Battle Against COVID-19

Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory are making progress on several fronts in the battle against COVID-19, the global pandemic sparked by the emergence of a novel coronavirus late last year. This work is part of a worldwide effort to understand the virus and the factors that affect its spread with the aim of devising treatments and other mitigation strategies.

CARES Act funds major upgrade to Corona supercomputer for COVID-19 work

With funding from the Coronavirus Aid, Relief and Economic Security (CARES) Act, Lawrence Livermore National Laboratory, chipmaker AMD and information technology company Supermicro have upgraded the supercomputing cluster Corona, providing additional resources to scientists for COVID-19 drug discovery and vaccine research

Researchers Identify “Druggable” Signaling Pathway that Stimulates Lung Tissue Repair

Researchers at Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania have identified a cellular pathway that can be targeted with a naturally occurring drug to stimulate lung tissue regeneration, which is necessary for recovery from multiple lung injuries. The findings, which were published today in Nature Cell Biology, could lead to better therapies for patients with lung disease, including acute respiratory distress syndrome (ARDS) due to COVID-19.